[The cardiac hazard of tocolysis and antagonizing possibilities. II. Communication: protection of the myocardium by means of substitution of magnesium].
In a comparative study the value of the substitution of magnesium for the evaluation of cardiac side-effects of tocolysis has been assessed with regard to haemodynamic as well as to metabolic and morphologic alterations. Haemodynamic studies at the thoracotomized dog using the technique described in the first publication showed significantly less severe haemodynamic alterations in a group with normal magnesium blood levels than in the second group with reduced magnesium blood levels. Significant differences could be found at systolic blood pressure, cardiac output, velocity and acceleration of pressure rising, total peripherial resistance, myocardial contraction status and myocardial oxygen consumption. Likewise, a beneficial tendency could be found at the parameters: heart rate, Bretschneiders index of inotropy, pulmonal arterial pressure and coronary reserve. During chronic experiments at the rat, the addition of magnesiumaspartate led to a significantly improved preservation of high-energy phosphates in the myocardium with a concomitant reduction of lactic acid output. Also the increase of body weight was significantly higher when substituting magnesium. Microscopic examination showed no irritations of myocardial structure within the magnesium-substituted group, whereas lymphocytic infiltrations and a slight fibrosis of the endocardium could be seen at the animals having received only Fenoterol. Together, these findings lead to the conclusion, that the substitution of magnesium can act prophylactically against cardiac alterations, induced by Fenoterol. Consequently, magnesium deficiency, which frequently accompanies pregnancy, should be balanced before starting a tocolytic therapy.
D000818:Animals; D001794:Blood Pressure; D002302:Cardiac Output; D009202:Cardiomyopathies / Q000139:chemically induced / Q000517:prevention & control; D004285:Dogs; D004983:Ethanolamines / Q000009:adverse effects*; D005260:Female; D005280:Fenoterol / Q000009:adverse effects*; D006331:Heart Diseases / Q000517:prevention & control*; D006339:Heart Rate; D008274:Magnesium / Q000627:therapeutic use*; D009200:Myocardial Contraction / Q000187:drug effects; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D051381:Rats; D014655:Vascular Resistance
D004983:Ethanolamines; D005280:Fenoterol; D008274:Magnesium
Das kardiale Risiko bei Tokolyse und Möglichkeiten zu dessen Antagonisierung. II. Mitteilung: Kardioprotektion durch Magnesiumsubstitution.